Xiaohong Yan

Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS ^G12C </i> Mutation

Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2022 · 984 citations · Full text

Medicine, Oncology, Pharmacology +15

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i>^<i>G12C</i> Solid Tumors (KRYSTAL-1)

Sai‐Hong Ignatius Ou, Pasi A. Jänne, Ticiana Leal et al. · Journal of Clinical Oncology · 2022 · 300 citations · Full text

Pharmacy, Oncology, Pharmacology +16

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Joshua K. Sabari, Haeseong Park, Anthony W. Tolcher et al. · Journal of Clinical Oncology · 2021 · 53 citations

Medicine, Oncology, Pharmacology +17

Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study

Yuntai Cao, Guojin Zhang, Jing Zhang et al. · Frontiers in Oncology · 2021 · 49 citations · Full text

Medicine, Oncology, Radiology +17

Inhibition of Endothelial Cell Proliferation and Tumor Angiogenesis by Up-Regulating NDRG2 Expression in Breast Cancer Cells

Ji Ma, Wenchao Liu, Xiaohong Yan et al. · PLoS ONE · 2012 · 41 citations · Full text

Medicine, Cancer Biology, Oncology +16